Business Description
Ceryvyn Therapeutics Limited, formerly Opthea Limited, is an Australian-American drug development company focused on treatments for serious eye conditions. Its lead drug, Sozinibercept, works by blocking specific proteins that cause abnormal blood vessel growth and is currently being tested in late-stage clinical trials for wet age-related macular degeneration and diabetic macular edema. Founded in 1984 and based in Melbourne, Australia, the company has spent decades building toward bringing new vision-saving therapies to patients.
